New hope for transplant patients fighting a devastating rejection

NCT ID NCT06343792

Recruiting now Disease control Sponsor: ReAlta Life Sciences, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called RLS-0071 for patients who develop a severe immune reaction (graft-versus-host disease) after a stem cell transplant and do not get better with standard steroid treatment. Researchers will give different doses to hospitalized patients to see if the drug is safe and if it can help control the disease. The main goals are to check for side effects and see how many patients respond to the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 1068
ACTIVE_NOT_RECRUITING

St Louis, Missouri, 63110, United States
Site 1091
ACTIVE_NOT_RECRUITING

Duarte, California, 91010, United States
Site 1100
ACTIVE_NOT_RECRUITING

Cincinnati, Ohio, 45229, United States
Site 1318
ACTIVE_NOT_RECRUITING

Atlanta, Georgia, 30041, United States
Site 1343
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90095, United States
Site 1382
ACTIVE_NOT_RECRUITING

Columbus, Ohio, 43210, United States
Site 3101
RECRUITING

Seville, SE, 41013, Spain
Site 3101
RECRUITING

Seville, Spain
Site 3227
RECRUITING

Salamanca, Spain
Site 3242
RECRUITING

Freiburg im Breisgau, 79106, Germany
Site 3360
RECRUITING

Madrid, Spain

Conditions

Explore the condition pages connected to this study.

STEROID REFRACTORY GVHD